DOI 10.1016/j.msard.2026.107204
Antinuclear antibody and delayed immunotherapy predict disease evolution in isolated optic neuritis-onset NMOSD: A long-term cohort study.
Аннотация
BACKGROUND
The disease course of neuromyelitis optica spectrum disorder (NMOSD) presenting with isolated optic neuritis (ON) is heterogeneous. Predictive factors for progression to other core phenotypes or bilateral ON (BON) remain poorly defined.
OBJECTIVE
To delineate disease evolution patterns and identify risk factors for phenotypic conversion and BON in a long-term cohort of ON-onset NMOSD, with a specific focus on the impact of antinuclear antibody (ANA) and the timing of immunosuppressive therapy (IMT).
METHODS
This single-center retrospective cohort study enrolled 231 AQP4-IgG-seropositive NMOSD patients with isolated ON onset (2010-2022). All had ≥3 years of follow-up (median 7 years). Disease evolution was categorized as: sustained isolated ON, conversion to other core phenotypes (e.g., myelitis), or progression from unilateral to BON. Multivariable Cox regression and logistic models were used to assess predictors, including ANA status and IMT initiation timing (Early: ≤3 months; Delayed: >3 months after first attack).
RESULTS
During follow-up, 35.1% (81/231) experienced phenotypic conversion, and 68.4% (130/190 of unilateral-onset cases) progressed to BON. Multivariable analyses identified ANA seropositivity (HR = 1.65, 95% CI 1.10-2.49, p=0.016) and delayed IMT initiation (HR = 2.76, 95% CI 1.12-6.77, p=0.027) as independent predictors of phenotypic conversion. For BON conversion, delayed IMT was the strongest independent risk factor (HR 3.23, 95% CI 1.49-7.00, p=0.003). Notably, among patients not receiving maintenance IMT (71/231), a subgroup (42/71, 59.2%) maintained minimal disability (EDSS ≤3), often in the setting of comorbidities contraindicating treatment; although this proportion declined substantially with very long-term follow-up.
CONCLUSION
In AQP4-IgG-positive NMOSD presenting with isolated ON, ANA seropositivity and delayed IMT are independent predictors of disease evolution toward more severe phenotypes, whereas longer follow-up duration itself confers a modest protective effect. These findings highlight a critical early therapeutic window for IMT and support risk-stratified, individualized management in this clinically diverse population.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.